Sigilon Therapeutics to Present Preclinical Data on Rare Blood Disorders at ASH

November 7, 2019

The following is a press release from Sigilon Therapeutics. Sigilon Therapeutics聽announced it will present data at the American Society of Hematology Annual Meeting demonstrating that its novel Shielded Living TherapeuticsTM platform for rare bleeding disorders remains viable in animal models for at least six months. The data also demonstrate dose-responsive in vivoexpression of human coagulation […]

Sigilon Therapeutics Receives Orphan Drug Designation for a Treatment of Hemophilia A

September 6, 2019

The following is a press release from Sigilon Therapeutics. Read the press release on the Sigilon website聽here. Sigilon Therapeutics聽has announced it has received Orphan Drug Designation for SIG-001, an investigational therapy for hemophilia A that leverages Sigilon鈥檚 Shielded Living Therapeutics™聽platform to implant cells engineered to produce stable blood plasma levels of factor VIII, a crucial […]

New Biopharmaceutical Company, Sigilon Therapeutics, Launches

July 7, 2017

Note: The following is an edited version of a press release from Sigilon聽Therapeutics.聽Read the press release from Sigilon聽Therapeutics聽in it鈥檚 entirety聽here. Flagship Pioneering, a fully-integrated life science innovation聽enterprise, recently聽announced the launch of Sigilon Therapeutics Inc. Sigilon Therapeutics is a聽biopharmaceutical company that discovers and develops category-defining biocompatible encapsulated聽cell therapies. Sigilon Therapeutics鈥 discovery platform combines cell engineering and […]

Sign up for E-mails, Dateline Magazine, and other ways to stay connected.